Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

Trial Profile

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Naloxone (Primary)
  • Indications Bulimia nervosa; Cocaine abuse; Drug abuse; Eating disorders; Opioid abuse
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 16 Mar 2016 According to Opiant Pharmaceuticals media release, dosing is expected to initiate in 1Q17 in eating disorders patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top